HomeClinical TopicsFDA approves Xeljanz for rheumatoid arthritis

FDA approves Xeljanz for rheumatoid arthritis

Author(s):

On Nov. 6, the U.S. Food and Drug Administration (FDA) approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

menopause and sleep problems

Menopause and Sleep Problems

Data shows that sleep disturbances increase in prevalence during the menopausal transition, with the most common complaint being nighttime awakenings. Take our quick three-question survey...